



ANNUAL REPORT

Fiscal Year 2018-2019





A Letter from our Executive Director



Over the past 20 years or so, CBAM's work has been recognized as agenda-setting, leading the science in development of new treatments for stimulant use disorder and addressing the impact of substance use on HIV. Our contributions to the scientific knowledge base in fiscal year 2018/2019 alone hit a record of 47 peer-reviewed journal articles covering a dizzying range of topics including

- The [stigma](#) and misperceptions that keep people from accessing medications proven to prevent HIV acquisition, and
- A follow-up that found three-fold increases in 20-year [mortality](#) rates for methamphetamine dependent gay and bisexual men living with HIV who smoked cigarettes compared to a non-drug using population of adult men in the U.S.

And already in fiscal year 2019/2020, we've had two major publications

- A high-impact paper on the concept of [social genomics](#) and the ways that stressful life events like intimate partner violence interact with gene expression to release pro-inflammatory cytokines. This has potential for evaluation as a biological marker that could correspond with abstinence outcomes from behavioral treatment for stimulant use disorder.
- A recent report in [the Lancet](#) provides the most comprehensive and current knowledge regarding stimulant use globally. This is a report that will be cited widely over the next five years.

This past year was also one of transition at CBAM. Members of our staff moved on to new positions with worthy organizations including City of Hope and the Los Angeles County Public Health Department. Dr. Emeka Okafor received his career development award and accepted an Assistant Professor position at the new Department of Epidemiology at Baylor University. Dr. Keith Heinzerling, long-time CBAM faculty member and founder/champion of our addiction medicine clinic, began a new position as Director of the Pacific Treatment & Research In Psychedelics (TRIP) Program. It is hard to let them go, but we are excited to see each of our CBAM family members grow and to make their mark.

At CBAM we have the privilege and joy of helping to develop cutting-edge treatments for addictions and for comorbidities of addictive disorders. We have led or been involved in the evaluation of every significant medication and behavioral therapy for stimulant use disorder. All of us at CBAM, our colleagues, our clinicians, and leaders within the Department of Family Medicine, encounter people whose need for addiction treatment and prevention overwhelm our systems of care. However, our successes in the field leave me with the confident assertion that, before I retire, one or more medication therapies for stimulant use disorder that emerges from our research will be implemented within the treatment delivery system.

With the [fourth wave](#) of the opioid epidemic clearly focused on methamphetamine, we have much to do in the next year. We embark on this new adventure with great excitement and we invite your participation as a CBAM member and as a donor. Together we will change the world.

A handwritten signature in black ink, appearing to be 'S. S. S.' or similar.



About CBAM

CBAM is a multidisciplinary center that seeks to advance the prevention and treatment of chronic illness, especially in communities with health disparities.

As part of the UCLA Department of Family Medicine, CBAM works at the intersection of academia and community with a focus on treating addictions and preventing the spread of HIV.

Key Performance Indicators



Research Visits

2,757 visits across multiple sites



Outpatient Clinic Visits

4,323 visits for behavioral therapy
and medication-assisted treatment



Faculty/Staff

40 full and part time employees



Annual Funding

\$7,471,091 for research, training
and clinical services



Peer-Reviewed Articles

47 published scientific manuscripts






Research Highlights



In pursuit of our mission, CBAM conducts research on medical, behavioral, and combination approaches to the prevention and treatment of chronic illnesses, with a particular focus on addiction and HIV. We stress the values of integrity and scientific rigor in the conduct of our research and work closely with the communities we serve to ensure that the best of care is given. The following pages highlight our research activities over the past year.





GSNAP Study

The UCLA Vine Street Clinic served as the site for the new GSNAP study. This project seeks to better understand how men who have sex with men use social networking sites to find substance use partners and sexual partners, which is critical to preventing HIV and sexually transmitted infections. Research participants provided social media data and came to clinic multiple times over a three month period to complete surveys and receive free HIV and STI screenings. The study is led by our close colleague, [Dr. Ian Holloway](#).




Visit Statistics

This year, there were a total of nine active research studies operating at our clinics and our hard-working staff successfully completed enrollment in four of them. They met or exceeded some very difficult targets, including

- enrollment of key populations, and
- high rates of retention

We completed 2,757 research visits with both first time and returning participants.






Our Research Participants

Our team at CBAM includes the most incredible people. Every day they exemplify our core values of integrity, scientific rigor, service to the community and teamwork. We know how great they are, but it is even more powerful when we hear it from our patients. The quote below is from a patient in one of our methamphetamine clinical trials:

The staff made all the difference for me in the study. Their professionalism is paramount, but their compassion, friendliness, sincerity, candid honesty, genuine respect, affection, and care is what ultimately kept me engaged and kept me returning in spite of my falls and shortcomings. No amount of compensation offered to me would have ever equaled the words and simple acts of empathy, tenderness, humanity, wisdom, care and pure and legitimate affection each and every one of these individuals demonstrated. Indeed, it is this that kept me returning over and over and it is this that I will miss the most. Thank you.

With Gratitude

And to show our gratitude to all of our patients, we threw appreciation events throughout the year with ice cream sundaes, fresh hot popcorn and coffee, lovingly prepared by our staff.





The Center for HIV Identification, Prevention, and Treatment Services (CHIPTS) is a collaboration of leading researchers promoting collaborative research, networking, and capacity building among HIV researchers and communities in efforts to eliminate new HIV infections and health disparities among key populations with HIV-associated comorbidities.

This year, CHIPTS welcomed new leadership with Dr. Norweeta Milburn stepping in as Director of the Development Core, overseeing our pilot study program and development of trainees and junior researchers. In addition, Dr. Nina Harawa has taken lead as the Director of our Policy Core, integrating policy issues into our research agendas and overseeing a range of experts in cost-effectiveness analysis, behavioral economics, evaluation, dissemination and the application of policy analytic methods.



In September, we co-hosted a conference entitled “Opioids and HIV in Los Angeles: Getting the Word Out to Communities and Providers”. In collaboration with the County of Los Angeles, the AIDS Education and Training Center and service providers from throughout the region, the goal of this event was to increase awareness and to provide information for service providers, community members and clients about the current opioid crisis and its associated link to HIV.

In May, we co-hosted to a half-day event, “HIV and Meth in Los Angeles County—the Crisis Continues”. More than 150 stakeholders attended this event which reviewed the latest data on meth use in LA County and highlighted its impact on HIV and health among key, high-risk populations. Information was also provided on the latest effective treatments, risk reduction strategies, and local resources.



CHIPTS awarded funding to young investigators for several pilot studies this year, including:


2018 Pilot Studies

<u>Investigator</u>	<u>Study Title</u>
Jesse Fletcher	Brief Depression Intervention to Optimize Intensive Methamphetamine Treatment among Gay and Bisexual Men who have Sex with Men
Latoya Small	HIV Positive African American Women in Urban Communities: Compounding Mental Health Challenges related to Adherence within the Context of Poverty
Evan Kreuger	Understanding Generational Differences in Mental Health and Substance Use Correlates of HIV Screening and Prevention Using a Nationally Representative Sample of Men Who Have Sex with Men

For more information on CHIPTS, visit the [website](#).



Scientific Publications



As scientists, our biggest impact comes from the knowledge we generate and share. It's that knowledge of what works, what doesn't and why that leads to better policy, better medicine and better lives for those we serve. This year, CBAM faculty and staff contributed to the publication of 47 peer-reviewed articles in scientific journals, a new record!

Highlights include results from the LA PrEP Stories project, discussing issues around PrEP-related stigma among MSM of color in Los Angeles.

- Brooks RA, Nieto O, Landrian A, Fehrenbacher A, Cabral A. Experiences of Pre-Exposure Prophylaxis (PrEP)-Related Stigma among Black MSM PrEP Users in Los Angeles. *Journal of Urban Health*. 2019 Jun 18:1-3.
- Brooks RA, Nieto O, Landrian A, Donohoe TJ. Persistent stigmatizing and negative perceptions of pre-exposure prophylaxis (PrEP) users: implications for PrEP adoption among Latino MSM. *AIDS Care*. 2019 Apr 3;31(4):427-35.

We continued to explore the damaging effects of substance use in combination with HIV.

- Passaro RC, Ramsey K, Segura ER, Lake JE, Reback CJ, Clark JL, Shoptaw S. Speed kills: Associations between methamphetamine use, HIV infection, tobacco use, and accelerated mortality among gay and bisexual men in Los Angeles, CA 20 years after methamphetamine dependence treatment. *Drug and alcohol dependence*. 2019 Feb 1;195:164-9.
- Gorbach PM, Javanbakht M, Shover CL, Bolan RK, Ragsdale A, Shoptaw S. Associations Between Cannabis Use, Sexual Behavior, and Sexually Transmitted Infections/Human Immunodeficiency Virus in a Cohort of Young Men Who Have Sex With Men. *Sexually transmitted diseases*. 2019 Feb 1;46(2):105-11.

And we commented on important considerations for future research on substance use.

- Ray LA, Lim AC, Shoptaw S. What defines a clinically meaningful outcome in the treatment of substance use disorders: 'Getting your life back'. *Addiction*. 2019 Jan;114(1):18-20.

To learn more and to read summaries of each article, visit our [website](#).



Scientific Presentations

In addition to class lectures and local community events, CBAM faculty gave presentations at several large conferences this year. :

Dr. Steve Shoptaw presented at the HIV Prevention Trials Network Annual Meeting. His well-received talk was entitled

- Addressing the Effects of Non-Injection Substance Use on HIV Viral Load

He also presented at the 10th International AIDS Society Conference on HIV Science in Mexico City. He gave a talk on

- The Impact of Mental Health and Substance Use Disorder on Reaching Global HIV Care and Prevention Targets

In addition, Dr. Ron Brooks presented at the CDC National HIV Prevention Conference in Atlanta! He presented two abstracts:

- "Using social media and digital technologies to engage and retain in care, and achieve viral suppression among youth and young adults living with HIV"; and
- "Experiences of pre-exposure prophylaxis (PrEP) stigma among Latino gay and bisexual men in Los Angeles."





Training, Evaluation & Capacity Building



Training
students, clinicians,
researchers, and
public health professionals

CBAM is dedicated to training future researchers.

This year we had our largest ever class of undergraduate student researchers. Madelyn Martinez, an LA native and current student at the University of Notre Dame, joined us last summer. UCLA undergrads Joshua Kim, Uma Ramaratnam, Brianna Reinhardt, Jasmine Hernandez and Uwaila Omokaro spent portions of the 2018/2019 school year with us reading selected peer-reviewed journal articles, attending lectures, and working with our faculty and postdoctoral fellows on independent research projects and poster presentations.

In addition to direct one-on-one mentorship, our Social Media Evaluation and Technical Assistance Center (ETAC) completed data collection this year across all 10 U.S. demonstration sites. This included participant, costing and intervention exposure data, which will be used to evaluate the effectiveness of using mobile technology and social media to engage and retain HIV-positive youth and young adults in medical care and help them achieve viral suppression. Data is now being analyzed and we expect to publish our findings in the coming year. More information on the project can be found [here](#).

After three extremely productive years, our fellow, Dr. Emeka Okafor, has accepted a full time faculty position at Baylor University where he will continue the work he started with CBAM through a NIDA-funded grant on "The impact of cannabinoids on inflammation, HIV viral load and symptoms of distress among persons living with HIV". We are excited for Emeka and look forward to on-going collaborations.






Clinical Services



CBAM's clinical services continue to grow with a record 4,323 visits (encounters) this past year. That includes addiction, behavioral and psychiatric services. Our largest service location continues to be the UCLA Family Health Center, our Department's primary care clinic located in Santa Monica. However, CBAM clinicians are in high demand, working closely with other departments at UCLA to provide services across three additional locations.

International Reach

One of our biggest highlights of this past year was our pre-conference satellite session, "*It Only Hurts a Little: Long-Acting Injectables for HIV Prevention and Treatment*," at the HIV Research For Prevention (HIVR4P) Conference in Madrid, Spain. The CHIPTS team led this event, held on Monday, October 22, 2018. It included two panels, one focused on HIV prevention and one on treatment. Our featured panelists came from across the globe with representatives from the U.S., Brazil, Zimbabwe, Vietnam, South Africa, Spain and Argentina. They led great conversations on the clinical, behavioral, policy, and community considerations associated with the implementation of long-acting injectable antiretrovirals for both HIV prevention and treatment.



We continued to build on our work in Cape Town, South Africa. Dr. Shoptaw spent two weeks at the University of Cape Town, mentoring junior investigators and meeting with colleagues to plan and develop new research incorporating biomedical and behavioral approaches to improve the lives of people struggling with HIV, addiction and other co-morbid conditions.



Media

Beautiful Boy Screening

This year saw the release of *Beautiful Boy*, a movie based on two best-selling memoirs from father and son David and Nic Sheff. Dr. Shoptaw provided consultation to David as he was writing the book and he attended a special screening of the film earlier this year, followed by a Q&A with the Sheffs.



Notable Quotes:

Dr. Steve Shoptaw was interviewed by KQED in April of 2019 about the return of California's methamphetamine epidemic...

"The bottom line is, as Americans, we have just so much tolerance to deal with addiction. And if the opioid users have taken that tolerance then there's no more [left for meth users]."

"..policymakers on the East Coast haven't kept up. All they see in their backyards are opioids, and so that's where the funding and attention go."

In February, Dr. Shoptaw was quoted by the Washington Post about his work to curtail the fentanyl epidemic before it hits California....

"We know we're in a privileged position to have been spared a lot of the fentanyl mess," he said, "and we want to keep it that way."

So far, the deadly fentanyl epidemic hasn't hit California. Here's why. [The Washington Post](#). February 4, 2019.

Meth Mania: From Biker Gangs to the Psych Ward, How Speed Came of Age in California. [KQED News](#) – The California Report. April 5, 2019.

It's Been a Rough Road for Program to Get Addicted Offers Off the Street. [Voices of San Diego](#). April 18, 2019.

San Diego's Effort to Reduce Prison Overcrowding is Hitting Some Snags. [Pacific Standard Magazine](#). April 24, 2019.

The Truth About Drug Dealers Lacing Cocaine with Fentanyl. [Vice](#). April 5, 2019.

As Meth Use Surges, First Responders Struggle To Help Those In Crisis. Health Shots – [NPR Morning Edition](#). May 1, 2019.

Meth Vs. Opioids: America Has Two Drug Epidemics, But Focuses On One. California Healthline, [Kaiser Health News](#). May 8, 2019.



CENTER FOR BEHAVIORAL & ADDICTION MEDICINE
 Financial Statement for Fiscal Year 2018/2019
 (July 1, 2018 through June 30, 2019)

INCOME	<u>Permanently Restricted</u>	<u>Temporarily Restricted</u>	<u>Unrestricted</u>	<u>Total</u>	<u>FY 2017/2018</u>
Federal Contracts & Grants	\$ 5,858,764	\$ -	\$ -	\$ 5,858,764	\$ 6,354,482
State/Local Contracts & Grants	\$ -	\$ -	\$ -	\$ -	\$ -
Subcontracts	\$ -	\$ -	\$ -	\$ -	\$ 201,952
Corporations	\$ 51,236	\$ -	\$ -	\$ 51,236	\$ -
Foundations	\$ 222,237	\$ -	\$ -	\$ 222,237	\$ 74,312
Individuals	\$ -	\$ -	\$ -	\$ -	\$ -
UC Funds	\$ -	\$ -	\$ 164,947	\$ 164,947	\$ 60,893
Clinical Services Income	\$ -	\$ 1,173,907	\$ -	\$ 1,173,907	\$ 803,920
TOTAL INCOME	\$ 6,132,237	\$ 1,173,907	\$ 164,947	\$ 7,471,091	\$ 7,495,559
EXPENSES					
Academic Salaries				\$ 850,081	\$ 703,491
Staff Salaries				\$ 1,763,962	\$ 1,720,896
Fringe Benefits				\$ 1,045,124	\$ 1,085,347
Stipends - Postdoctoral Fellows				\$ -	\$ 53,668
Stipends - Interns				\$ -	\$ 3,130
Consultants/Guest Lecturers				\$ 32,246	\$ 18,475
Employee Training/Certifications/Licenses/Memberships				\$ 540	\$ 4,632
Subawards				\$ 84,989	\$ 135,286
Funds Transferred to Other Departments (Direct)				\$ 925,608	\$ 907,683
Space Rental				\$ 187,613	\$ 171,555
Alterations/Renovations				\$ 6,172	\$ 48,637
Communications				\$ 49,680	\$ 48,872
Clinic Operations				\$ 50,586	\$ 37,023
General Supplies & Equipment				\$ 2,088	\$ 4,106
Computers, Software & Computer Supplies				\$ 21,647	\$ 40,302
Medical Supplies				\$ 26,013	\$ 46,111
Project-Related Supplies				\$ 50,408	\$ 49,196
Travel and Events				\$ 146,143	\$ 117,863
Postage/Courier				\$ 39,475	\$ 42,198
Print/Copy Services				\$ 5,957	\$ 4,011
Recruitment Ads				\$ 128,112	\$ 111,504
Lab Services				\$ 142,533	\$ 153,946
Pharmacy				\$ 52,676	\$ 73,627
Inpatient Care				\$ 112,513	\$ 121,685
Participant Incentives				\$ 142,691	\$ 176,965
Miscellaneous				\$ 1,816	\$ 1,737
Indirect Charges				\$ 1,401,173	\$ 1,430,147
TOTAL EXPENSES				\$ 7,269,848	\$ 7,312,092
NET INCOME (LOSS) YTD*				\$ 201,243	\$ 183,467


This document was generated internally. It is not an audited financial statement.

**The net balance is primarily restricted project funding that will carryover into the next fiscal year.*



Show your support!

To help support this life-changing work, visit us at <http://www.uclacbam.org/about-us/donate/> or call (310) 794-0645 to speak with our Administrative Director. More than 90% of every donation goes directly to serve our mission and all donations are tax deductible. Naming opportunities are available!



Contact Us!

UCLA Center for Behavioral &
Addiction Medicine
10880 Wilshire Blvd., Ste. 1800
Los Angeles, CA 90024
(310) 794-0619
cbam@mednet.ucla.edu
cbam.ucla.edu